Defeating Cancer Resistance
Black Diamond Therapeutics (blackdiamondtherapeutics.com) scores 65 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 11th percentile of 10279 Healthcare brands.
Black Diamond Therapeutics is a precision oncology company focused on developing 'MasterKey' therapies designed to target multiple oncogenic mutations simultaneously, rather than a single mutation as traditional targeted therapies do. Its stated mission is to defeat cancer resistance and expand the population of patients who can benefit from targeted treatment. The company positions itself as a pioneer of this MasterKey approach within the oncology research and treatment landscape, serving cancer patients, oncologists, and the broader healthcare and research community.
| Brand Name | Black Diamond Therapeutics |
|---|---|
| Domain | blackdiamondtherapeutics.com |
| Industry | Healthcare |
| Main Competitors | Relay Therapeutics (75/100), Revolution Medicines (82/100), Blueprint Medicines (79/100), Mirati Therapeutics (83/100), Turning Point Therapeutics |
Moz Domain Authority 35/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "To defeat cancer resistance by developing MasterKey therapies that address many oncogenic mutations with one solution." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:type. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx.
Social footprint: verified profiles on LinkedIn, Facebook, Instagram; no detected presence on X (Twitter), YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Black Diamond Therapeutics?", Claude could identify the brand as of September 2026. Black Diamond Therapeutics is a biopharmaceutical company focused on developing precision oncology medicines that target mutant-selective driver mutations in cancer, using its proprietary MAP (Mutation-Allostery-Pharmacology) platform to identify and design small molecule inhibit Best known for Developing precision oncology drugs targeting allosteric mutations, including its lead candidate BDTX-1935 for EGFR/HER2 mutant cancers.
When asked "Best brands similar to Black Diamond Therapeutics?", Claude would recommend Black Diamond Therapeutics as of September 2026. It's a legitimate clinical-stage precision oncology company worth mentioning if someone is asking about biotech firms working on mutant-selective cancer therapies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Black Diamond Therapeutics's main competitors in Healthcare: Relay Therapeutics (75/100), Revolution Medicines (82/100), Blueprint Medicines (79/100), Mirati Therapeutics (83/100).
Sources: Brand Analyzer scan
Black Diamond Therapeutics has low AI-search visibility, scoring 22/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 36, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Black Diamond Therapeutics scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Black Diamond Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Black Diamond Therapeutics is a precision oncology company that develops 'MasterKey' therapies aimed at addressing multiple oncogenic mutations with a single treatment solution, with the goal of overcoming cancer resistance seen in traditional targeted therapies.
Black Diamond Therapeutics scores 22/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Black Diamond Therapeutics has a weak AI-visibility profile at 22/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 35/100. In a live check, Claude could already identify Black Diamond Therapeutics from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Black Diamond Therapeutics: Biohacking Performance (65/100), BigHat Biosciences (65/100), BrightStar Care (65/100), Bubs Australia (65/100).
A step up - brands to learn from: ZT Corporate (71/100), Zorgnet-Icuro (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.